Cargando…

Experience with ospemifene in patients with vulvar and vaginal atrophy: case studies with bone marker profiles

Selective estrogen receptor modulators (SERMs) exhibit varying agonist/antagonist activities on estrogen receptors in tissues, although most SERMs, including ospemifene, have agonist effects on bone. In this article, outcomes in relation to bone homeostasis, bone mineral density (BMD), and osteopeni...

Descripción completa

Detalles Bibliográficos
Autores principales:	del Carmen Pingarrón Santofimia, María, Rodríguez, Silvia Pilar González, Lilue, Mariella, Palacios, Santiago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337603/ https://www.ncbi.nlm.nih.gov/pubmed/32670383 http://dx.doi.org/10.7573/dic.2020-3-3

Ejemplares similares

Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies
por: Lilue, Mariella, et al.
Publicado: (2020)

Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies
por: Blanco, Zuramis Estrada, et al.
Publicado: (2020)

Ospemifene for vulvar and vaginal atrophy: an overview
por: Palacios, Santiago
Publicado: (2020)

Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy
por: Palacios, Santiago, et al.
Publicado: (2016)

The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy
por: Nappi, R. E., et al.
Publicado: (2015)

Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy
por: Bruyniks, N., et al.
Publicado: (2016)

Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast
por: Soe, Lin H, et al.
Publicado: (2013)

Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies
por: López, Ana Rosa Jurado, et al.
Publicado: (2020)

Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy
por: Goldstein, S. R., et al.
Publicado: (2014)

Effect of Ospemifene on Densitometric and Plasma Bone Metabolism Biomarkers in Postmenopausal Women Reporting Vulvar and Vaginal Atrophy (VVA)
por: Maffei, Silvia, et al.
Publicado: (2022)

Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause
por: Wurz, Gregory T, et al.
Publicado: (2014)

Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use
por: Cagnacci, Angelo, et al.
Publicado: (2020)

Ospemifene May Not Treat Vulvar Atrophy: A Report of Two Cases
por: Goldstein, Andrew T., et al.
Publicado: (2016)

Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices
por: Goldstein, Irwin, et al.
Publicado: (2019)

Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial
por: Constantine, G., et al.
Publicado: (2015)

Experience with ospemifene in a patient with vulvovaginal atrophy and dyslipidemia: a case study
por: Rodríguez, Silvia Pilar González
Publicado: (2020)

Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy
por: Shin, Jae Jun, et al.
Publicado: (2017)

Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey
por: Nappi, R. E., et al.
Publicado: (2016)

Vaginal dehydroepiandrosterone compared to other methods of treating vaginal and vulvar atrophy associated with menopause
por: Pięta, Wojciech, et al.
Publicado: (2021)

Experience with ospemifene in patients with vulvovaginal atrophy treated with laser therapy: case studies
por: Salcedo, Félix Lugo, et al.
Publicado: (2020)

Clinical study of the tolerability of calcium carbonate–casein microcapsules as a dietary supplement in a group of postmenopausal women
por: Palacios, Santiago, et al.
Publicado: (2020)

Vulvar and Vaginal Melanomas—The Darker Shades of Gynecological Cancers
por: Dobrică, Elena-Codruța, et al.
Publicado: (2021)

Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis
por: Simon, James A., et al.
Publicado: (2023)

Human papillomavirus in vulvar and vaginal carcinoma cell lines
Publicado: (1995)

Human papillomavirus in vulvar and vaginal carcinoma cell lines.
por: Hietanen, S., et al.
Publicado: (1995)

Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial
por: Archer, David F., et al.
Publicado: (2019)

WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history
por: Kingsberg, Sheryl A., et al.
Publicado: (2019)

The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy
por: Constantine, Ginger D., et al.
Publicado: (2017)

Endometrial safety of ospemifene: results of the phase 2/3 clinical development program
por: Constantine, Ginger D., et al.
Publicado: (2015)

Early Effect of 0.005% Estriol Vaginal Gel on Symptoms and Signs of Vulvovaginal Atrophy
por: Lázaro-Carrasco de la Fuente, Jesús, et al.
Publicado: (2022)

Other Gynecologic Cancers: endometrial, ovarian, vulvar and vaginal cancers
por: Duarte-Franco, Eliane, et al.
Publicado: (2004)

Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark
por: Olsen, Jens, et al.
Publicado: (2012)

Vaginal microbiota signatures in healthy and purulent vulvar discharge sows
por: Poor, André P., et al.
Publicado: (2022)

Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study
por: Nordstrom, Beth L., et al.
Publicado: (2022)

Gynecologic tumor board: a radiologist’s guide to vulvar and vaginal malignancies
por: Chow, Lucy, et al.
Publicado: (2021)

Effects of Ospemifene on Drug Metabolism Mediated by Cytochrome P450 Enzymes in Humans in Vitro and in Vivo
por: Turpeinen, Miia, et al.
Publicado: (2013)

Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence
por: Archer, David F., et al.
Publicado: (2015)

Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials
por: Simon, James A., et al.
Publicado: (2018)

Maternal and fetal ultrasonography, vulvar temperature and vaginal mucous impedance for the prediction of parturition in Saanen does
por: Del’Aguila-Silva, Priscila, et al.
Publicado: (2023)

Quality assessment of the registration of vulvar and vaginal premalignant lesions at the Cancer Registry of Norway
por: Enerly, Espen, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_02dhqsijsf91p1q1vso1stlrkf